HLN vs. HUM, CNC, GEHC, ALC, MRNA, IDXX, IQV, TAK, BIIB, and WST
Should you be buying Haleon stock or one of its competitors? The main competitors of Haleon include Humana (HUM), Centene (CNC), GE HealthCare Technologies (GEHC), Alcon (ALC), Moderna (MRNA), IDEXX Laboratories (IDXX), IQVIA (IQV), Takeda Pharmaceutical (TAK), Biogen (BIIB), and West Pharmaceutical Services (WST). These companies are all part of the "medical" sector.
Humana (NYSE:HUM) and Haleon (NYSE:HLN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.
Humana received 873 more outperform votes than Haleon when rated by MarketBeat users. Likewise, 64.15% of users gave Humana an outperform vote while only 39.29% of users gave Haleon an outperform vote.
Humana pays an annual dividend of $3.54 per share and has a dividend yield of 1.2%. Haleon pays an annual dividend of $0.21 per share and has a dividend yield of 2.5%. Humana pays out 22.0% of its earnings in the form of a dividend. Haleon pays out 75.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Humana has raised its dividend for 7 consecutive years.
Humana has higher revenue and earnings than Haleon. Humana is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.
Humana currently has a consensus target price of $433.74, suggesting a potential upside of 41.79%. Given Haleon's higher possible upside, equities research analysts plainly believe Humana is more favorable than Haleon.
Haleon has a net margin of 9.28% compared to Haleon's net margin of 1.82%. Haleon's return on equity of 17.76% beat Humana's return on equity.
In the previous week, Humana had 54 more articles in the media than Haleon. MarketBeat recorded 56 mentions for Humana and 2 mentions for Haleon. Humana's average media sentiment score of 0.85 beat Haleon's score of 0.41 indicating that Haleon is being referred to more favorably in the news media.
92.4% of Humana shares are owned by institutional investors. Comparatively, 6.7% of Haleon shares are owned by institutional investors. 0.3% of Humana shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Humana has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Haleon has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.
Summary
Humana beats Haleon on 14 of the 21 factors compared between the two stocks.
Get Haleon News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
